361 related articles for article (PubMed ID: 28612269)
1. Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.
Stage TB; Bergmann TK; Kroetz DL
Clin Pharmacokinet; 2018 Jan; 57(1):7-19. PubMed ID: 28612269
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
Siqing F; Culotta KS; Falchook GS; Hong DS; Myers AL; Zhang YP; Naing A; Janku F; Hou MM; Kurzrock R
Cancer Chemother Pharmacol; 2016 Feb; 77(2):357-64. PubMed ID: 26698868
[TBL] [Abstract][Full Text] [Related]
3. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.
Chen N; Li Y; Ye Y; Palmisano M; Chopra R; Zhou S
J Clin Pharmacol; 2014 Oct; 54(10):1097-107. PubMed ID: 24719309
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
Tsushima T; Kasai H; Tanigawara Y
Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
[TBL] [Abstract][Full Text] [Related]
6. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
7. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
[TBL] [Abstract][Full Text] [Related]
8. Albumin-bound paclitaxel: a next-generation taxane.
Gradishar WJ
Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
[TBL] [Abstract][Full Text] [Related]
9. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
Li Y; Kassir N; Chen N; Wang X; Palmisano M; Zhou S
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):115-130. PubMed ID: 32459889
[TBL] [Abstract][Full Text] [Related]
11. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
Moreno L; Casanova M; Chisholm JC; Berlanga P; Chastagner PB; Baruchel S; Amoroso L; Gallego Melcón S; Gerber NU; Bisogno G; Fagioli F; Geoerger B; Glade Bender JL; Aerts I; Bergeron C; Hingorani P; Elias I; Simcock M; Ferrara S; Le Bruchec Y; Slepetis R; Chen N; Vassal G
Eur J Cancer; 2018 Sep; 100():27-34. PubMed ID: 29936064
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients.
Borgå O; Lilienberg E; Bjermo H; Hansson F; Heldring N; Dediu R
Adv Ther; 2019 Oct; 36(10):2825-2837. PubMed ID: 31432461
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
Danesi R; Innocenti F; Fogli S; Gennari A; Baldini E; Di Paolo A; Salvadori B; Bocci G; Conte PF; Del Tacca M
Br J Clin Pharmacol; 2002 May; 53(5):508-18. PubMed ID: 11994057
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
Briasoulis E; Karavasilis V; Tzamakou E; Haidou C; Piperidou C; Pavlidis N
Anticancer Drugs; 2002 Jun; 13(5):481-9. PubMed ID: 12045459
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
J Clin Oncol; 2002 Jan; 20(2):574-81. PubMed ID: 11786588
[TBL] [Abstract][Full Text] [Related]
16. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study.
Biakhov MY; Kononova GV; Iglesias J; Desai N; Bhar P; Schmid AN; Loibl S
Expert Opin Drug Saf; 2010 Jul; 9(4):515-23. PubMed ID: 20500029
[TBL] [Abstract][Full Text] [Related]
17. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
Rischin D; Webster LK; Millward MJ; Linahan BM; Toner GC; Woollett AM; Morton CG; Bishop JF
J Natl Cancer Inst; 1996 Sep; 88(18):1297-301. PubMed ID: 8797769
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
Nyman DW; Campbell KJ; Hersh E; Long K; Richardson K; Trieu V; Desai N; Hawkins MJ; Von Hoff DD
J Clin Oncol; 2005 Nov; 23(31):7785-93. PubMed ID: 16258082
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
20. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos WJ; Sparreboom A
Anticancer Drugs; 2000 Jun; 11(5):331-7. PubMed ID: 10912949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
